• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    2/9/22 3:24:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMGN alert in real time by email
    SC 13G/A 1 tv0251-amgeninc.htm SCHEDULE 13G/A amgeninc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Amgen Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  031162100

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  031162100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    954,537

    7.  SOLE DISPOSITIVE POWER

    44,278,644

    8.  SHARED DISPOSITIVE POWER

    2,382,365

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    46,661,009

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.28%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Amgen Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    One Amgen Center Drive
    Thousand Oaks, CA 91320-1799

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    031162100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMGN

    DatePrice TargetRatingAnalyst
    5/20/2025$288.00Neutral
    Guggenheim
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    12/10/2024$256.00Underperform
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/14/2024$335.00Neutral
    Citigroup
    10/17/2024$380.00Outperform
    Bernstein
    10/14/2024$320.00 → $333.00Buy → Hold
    Truist
    9/27/2024$405.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      11/21/24 12:43:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for PAVBLU issued to AMGEN INC

      Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

      8/26/24 5:53:38 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      8/21/24 12:12:47 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

      4 - AMGEN INC (0000318154) (Reporting)

      9/19/23 7:52:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    SEC Filings

    See more
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:46:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:42:09 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Amgen Inc.

      10-Q - AMGEN INC (0000318154) (Filer)

      5/1/25 6:54:46 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

      MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes  New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT  THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio

      6/18/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Business Development Khosla Rachna sold $434,520 worth of shares (1,500 units at $289.68), decreasing direct ownership by 16% to 8,162 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      6/6/25 7:49:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miles Amy E was granted 809 shares, increasing direct ownership by 20% to 4,842 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:07:13 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kullman Ellen Jamison was granted 809 shares, increasing direct ownership by 6% to 13,467 units (SEC Form 4)

      4 - AMGEN INC (0000318154) (Issuer)

      5/28/25 9:06:19 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Amgen with a new price target

      Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

      5/20/25 8:11:08 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Amgen with a new price target

      Cantor Fitzgerald resumed coverage of Amgen with a rating of Neutral and set a new price target of $305.00

      4/22/25 7:29:10 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities resumed coverage on Amgen with a new price target

      BofA Securities resumed coverage of Amgen with a rating of Underperform and set a new price target of $256.00

      12/10/24 8:12:28 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS

      THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.  Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Committee and its Governance and Nominating Committee.  Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent. Dr. Drake is president of the University of California, a system of 10 campuses, five medical centers and three nationally affiliated labs that serves more than 280,000 students and employs 230,000 faculty and staff. "Michael is an accomplished physician an

      8/3/22 4:05:00 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Financials

    Live finance-specific insights

    See more
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

      MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes  New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT  THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio

      6/18/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      2/13/24 4:58:51 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      1/30/24 11:35:57 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Amgen Inc.

      SC 13D - AMGEN INC (0000318154) (Filed by)

      9/27/23 7:30:51 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care